BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33852571)

  • 1. Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.
    Khairnar R; Pugh SL; Sandler HM; Lee WR; Villalonga Olives E; Mullins CD; Palumbo FB; Bruner DW; Shaya FT; Bentzen SM; Shah AB; Malone SC; Michalski JM; Dayes IS; Seaward SA; Albert M; Currey AD; Pisansky TM; Chen Y; Horwitz EM; DeNittis AS; Feng FY; Mishra MV
    PLoS One; 2021; 16(4):e0249123. PubMed ID: 33852571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415.
    Khairnar R; DeMora L; Sandler HM; Lee WR; Villalonga-Olives E; Mullins CD; Palumbo FB; Bruner DW; Shaya FT; Bentzen SM; Shah AB; Malone S; Michalski JM; Dayes IS; Seaward SA; Albert M; Currey AD; Pisansky TM; Chen Y; Horwitz EM; DeNittis AS; Feng F; Mishra MV
    JCO Clin Cancer Inform; 2022 Jun; 6():e2100188. PubMed ID: 35776901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping EQ5D utilities from forced vital capacity and diffusing capacity in fibrotic interstitial lung disease.
    Wong AW; Sun H; Cox IA; Fisher JH; Khalil N; Johannson KA; Marcoux V; Assayag D; Manganas H; Kolb M; Palmer AJ; de Graaff B; Walters EH; Hopkins P; Zappala C; Goh NS; Moodley Y; Navaratnam V; Corte TJ; Ryerson CJ; Zhang W
    PLoS One; 2023; 18(3):e0283110. PubMed ID: 37000790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting utility scores for prostate cancer: mapping the Prostate Cancer Index to the Patient-Oriented Prostate Utility Scale (PORPUS).
    Bremner KE; Mitsakakis N; Wilson L; Krahn MD
    Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):47-56. PubMed ID: 24126796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer.
    Shaikh T; Li T; Handorf EA; Johnson ME; Wang LS; Hallman MA; Greenberg RE; Price RA; Uzzo RG; Ma C; Chen D; Geynisman DM; Pollack A; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):722-731. PubMed ID: 28244407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
    Yang Q; Yu XX; Zhang W; Li H
    Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys.
    Zamora V; Garin O; Pardo Y; Pont À; Gutiérrez C; Cabrera P; Gómez-Veiga F; Pijoan JI; Litwin MS; Ferrer M;
    Value Health; 2021 Nov; 24(11):1676-1685. PubMed ID: 34711369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting health-related quality of life (EQ-5D-5 L) and capability wellbeing (ICECAP-A) in the context of opiate dependence using routine clinical outcome measures: CORE-OM, LDQ and TOP.
    Peak J; Goranitis I; Day E; Copello A; Freemantle N; Frew E
    Health Qual Life Outcomes; 2018 May; 16(1):106. PubMed ID: 29843726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.
    Meregaglia M; Borsoi L; Cairns J; Tarricone R
    Eur J Health Econ; 2019 Mar; 20(2):181-193. PubMed ID: 28948436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
    Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
    Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People's Quality of Life Brief Questionnaire (OPQoL-Brief) Scores.
    Kaambwa B; Ratcliffe J
    Patient; 2018 Feb; 11(1):39-54. PubMed ID: 28623629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping the COPD Assessment Test onto EQ-5D.
    Hoyle CK; Tabberer M; Brooks J
    Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
    Wei JT; Dunn RL; Litwin MS; Sandler HM; Sanda MG
    Urology; 2000 Dec; 56(6):899-905. PubMed ID: 11113727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score.
    Dakin H; Gray A; Murray D
    Qual Life Res; 2013 Apr; 22(3):683-94. PubMed ID: 22555470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data.
    Kim HL; Kim D; Jang EJ; Lee MY; Song HJ; Park SY; Cho SK; Sung YK; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim J; Kim SK; Kim TH; Kim TJ; Koh E; Lee H; Lee HS; Lee J; Lee SS; Lee SW; Park SH; Shim SC; Yoo DH; Yoon BY; Bae SC; Lee EK
    Rheumatol Int; 2016 Apr; 36(4):505-13. PubMed ID: 26849891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping EQ-5D utility scores from the PedsQL™ generic core scales.
    Khan KA; Petrou S; Rivero-Arias O; Walters SJ; Boyle SE
    Pharmacoeconomics; 2014 Jul; 32(7):693-706. PubMed ID: 24715604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
    Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
    Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.